Table of Contents
Overview
New York, NY – May 27, 2025 – Global Cancer Therapeutics and Biotherapeutics Market size is expected to be worth around US$ 417.2 Billion by 2034 from US$ 184.5 Billion in 2024, growing at a CAGR of 8.5% during the forecast period 2025 to 2034.
The global cancer therapeutics and biotherapeutics market is undergoing rapid transformation, driven by continuous innovations in immunotherapy, targeted drug delivery, and cell-based therapies. With cancer remaining one of the leading causes of death worldwide, the demand for effective, personalized, and minimally invasive treatment options is steadily rising. According to data from the World Health Organization (WHO), cancer accounted for nearly 10 million deaths globally in 2022, underscoring the urgent need for advanced therapeutic solutions.
Biotherapeutics such as monoclonal antibodies, CAR-T cell therapy, and immune checkpoint inhibitors are significantly improving patient outcomes, particularly in treating hematologic malignancies and solid tumors. These therapies are increasingly being integrated into first-line treatment regimens across various cancer types, including breast, lung, and colorectal cancers.
Pharmaceutical companies and research institutes are investing heavily in clinical trials and regulatory approvals. The U.S. Food and Drug Administration (FDA) has accelerated the approval of several biologics under its breakthrough therapy and fast track designations, facilitating faster patient access to novel treatments.
North America currently dominates the market due to a strong healthcare infrastructure and high R&D investments, while Asia-Pacific is projected to witness the fastest growth owing to rising cancer incidence and healthcare reforms.
Key Takeaways
- Market Size: In 2023, the global cancer therapeutics and biotherapeutics market was valued at approximately US$ 184.5 billion. The market is projected to expand at a compound annual growth rate (CAGR) of 8.5%, reaching an estimated US$ 417.2 billion by 2033.
- Product Type Analysis: The market is categorized into chemotherapy, hormone therapy, radiation therapy, biotherapy, and others. Among these, chemotherapy emerged as the leading segment, accounting for 52.4% of the total market share in 2023.
- Application Analysis: The market is segmented into lung cancer, blood cancer, breast cancer, prostate cancer, and others. Lung cancer held the dominant position, contributing 43.2% of the global market revenue.
- End-use Analysis: The market is classified into hospitals, ambulatory surgical centers (ASC), and others. The hospital segment was the most significant contributor, capturing 61.3% of the total revenue in 2023.
- Regional Analysis: North America led the global market, holding a 41.6% share in 2023. This leadership is attributed to advanced healthcare infrastructure, high cancer prevalence, and strong investments in innovative therapeutic development.
Segmentation Analysis
- By Product Type Analysis: In 2023, chemotherapy led the cancer therapeutics market with a 52.4% share due to its continued use in treating various cancer types. It remains essential for both solid tumors and blood cancers. Rising cancer cases globally, combined with improved drug formulations and supportive care, are boosting its use. Chemotherapy is increasingly combined with immunotherapies and targeted therapies to enhance outcomes, especially as personalized cancer treatment gains traction.
- By Application Analysis: Lung cancer accounted for 43.2% of the application segment in 2023, driven by its high global incidence and mortality rate. Rising smoking rates and air pollution are key contributors. Advances in targeted therapy and immunotherapy, particularly for non-small cell lung cancer, are supporting market growth. Personalized medicine approaches focused on genetic mutations are further enhancing treatment effectiveness, while new drug approvals continue to expand therapeutic options for lung cancer patients.
- By End-Use Analysis: Hospitals dominated the end-use segment in 2023 with a 61.3% revenue share. This leadership is due to the increasing number of cancer patients requiring specialized therapies. Hospitals offer comprehensive treatment options including chemotherapy, radiation, and immunotherapy under expert care. The expansion of hospital infrastructure and integration of advanced technologies support this trend. The rise of multidisciplinary cancer care centers within hospitals is also improving patient access to personalized and effective treatment plans.
Market Segments
By Product Type
- Chemotherapy
- Hormone Therapy
- Radiation Therapy
- Biotherapy
- Others
By Application
- Lung Cancer
- Blood Cancer
- Breast Cancer
- Prostate Cancer
- Others
By End-use
- Hospital
- ASC
- Others
Regional Analysis
North America Leads the Cancer Therapeutics and Biotherapeutics Market
In 2023, North America emerged as the leading regional market, accounting for the highest revenue share of 41.6%. This dominance can be attributed to significant advancements in immunotherapies, targeted treatments, and sustained investment in oncology research. The region’s well-established healthcare infrastructure, along with rising awareness of personalized cancer therapies, has driven the adoption of innovative treatment solutions.
A notable development in 2023 was the U.S. FDA’s approval of 11 oncology drugs and biologics, specifically designed for pediatric cancer patients. This milestone underscores the region’s commitment to expanding treatment options across age groups. The increasing incidence of cancer and growing demand for biologics such as monoclonal antibodies and gene therapies continue to support market growth. Furthermore, the expanding focus on precision medicine and strong collaboration between pharmaceutical companies and academic institutions are expected to reinforce North America’s leadership in the global market.
Asia Pacific to Register the Highest CAGR During the Forecast Period
The Asia Pacific region is anticipated to witness the fastest compound annual growth rate (CAGR) over the forecast period. This rapid expansion is driven by the rising cancer burden, advancements in healthcare infrastructure, and increasing access to innovative therapies. Major countries such as China, India, and Japan are investing in cancer treatment and research, leading to higher adoption of biotherapeutics.
The modernization of healthcare systems across the region is facilitating the use of advanced therapies, including immunotherapy, targeted therapy, and gene-based treatments. Regional and multinational pharmaceutical companies are accelerating the development of novel biologic drugs, supported by favorable government initiatives and funding for cancer research. With a growing emphasis on personalized treatment plans, the cancer therapeutics and biotherapeutics market in Asia Pacific is expected to experience robust and sustained growth.
Emerging Trends
- Expansion of CAR T-Cell Therapies: The use of chimeric antigen receptor (CAR) T-cell therapies has increased markedly since the first approval in 2017. As of early 2025, six distinct CAR T-cell products have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of blood cancers such as leukemia and lymphoma. This growth reflects the ability of these “living drugs” to induce deep remissions in patients with relapsed or refractory disease.
- Adoption of Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors: Therapies based on tumor-infiltrating lymphocytes have moved beyond blood cancers. In February 2024, lifileucel (Amtagvi) became the first TIL therapy approved by the FDA for unresectable or metastatic melanoma. This milestone highlights the potential of adoptive cell therapies to target solid tumors that were previously resistant to immunotherapy.
- Growth of Bispecific T-Cell Engagers: Bispecific antibodies that bridge T cells to cancer cells are gaining traction. In June 2024, the FDA approved blinatumomab (Blincyto) for CD19-positive B-cell precursor acute lymphoblastic leukemia in both adults and children. This agent exemplifies next-generation monoclonal approaches that engage a patient’s own T cells to kill tumor cells.
- Emergence of Gene-Edited “Off-the-Shelf” CAR T Products: Allogeneic CAR T therapies are being investigated to overcome the logistical challenges of patient-specific manufacturing. Phase I studies of CRISPR-edited CAR T cells (e.g., CB-012 targeting CLL-1 and CB-011 targeting BCMA) are underway to test safety and early efficacy in acute myeloid leukemia and multiple myeloma. These trials aim to create universal cell products that can be stocked and administered without individual customization.
- Introduction of T Cell Receptor (TCR) Gene Therapies: TCR-engineered cell therapies are now reaching the clinic. In August 2024, afamitresgene autoleucel (TECELRA) was granted accelerated approval as the first T cell receptor gene therapy for unresectable or metastatic synovial sarcoma. This approval marks an important trend toward targeting intracellular cancer antigens via engineered T cells.
Use Cases
- Relapsed/Refractory Large B-Cell Lymphoma (CAR T-Cell Therapy): In the ZUMA-3 study of brexucabtagene autoleucel (Tecartus) for adults with B-cell precursor acute lymphoblastic leukemia, more than half of over 50 participants achieved complete remission within three months. Many of these patients maintained remission for over a year.
- Unresectable or Metastatic Melanoma (TIL Therapy): Following surgical harvest of tumor tissue, lifileucel TIL therapy led to objective responses in a substantial fraction of heavily pretreated melanoma patients. This single-dose approach provided new options for approximately 5,000 patients globally who are ineligible for checkpoint inhibitors.
- CD19-Positive B-Cell Precursor ALL (Bispecific Antibody): Blinatumomab, a bispecific CD3-CD19 engager, has been used in over 2,000 treated patients since its accelerated approval. It is indicated for adults and children as young as one month old with minimal residual disease ≥ 0.1% or relapsed/refractory disease.
- Multiple Myeloma (Allogeneic CAR T Trial): Early phase trials of CB-011, an allogeneic CRISPR-edited anti-BCMA CAR T therapy, are recruiting at over 10 clinical sites. These studies aim to enroll 30–40 patients per cohort, with safety and pharmacokinetics as primary endpoints.
- Synovial Sarcoma (TCR Gene Therapy): Afamitresgene autoleucel targets the MAGE-A4 antigen in HLA-A\02-positive patients. The pivotal trial enrolled around 80 participants, demonstrating objective responses in approximately 25% of patients, establishing proof of concept for TCR-based approaches in solid tumors.
Conclusion
The global cancer therapeutics and biotherapeutics market is advancing rapidly, fueled by innovations in immunotherapy, targeted treatments, and cell-based therapies. With rising cancer prevalence and the shift toward personalized medicine, demand for advanced therapeutic solutions continues to grow.
Emerging technologies such as CAR-T, TIL, bispecific antibodies, and gene-edited therapies are reshaping treatment paradigms and improving outcomes across multiple cancer types. Strong regulatory support, increasing R&D investments, and regional expansions especially in North America and Asia Pacific are further accelerating market growth. These trends collectively indicate a transformative decade ahead for cancer care and therapeutic innovation worldwide.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
